NEW YORK, NY / ACCESSWIRE / March 10, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Nutanix, Inc. (NASDAQ:NTNX)
Class Period: March 1, 2018 - May 30, 2019
Lead Plaintiff Deadline: March 22, 2021
During the class period, Nutanix, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: Nutanix had materially overstated its customer base and sales productivity, and that such overstatements would eventually cause the Company's stock price to drop dramatically.
Learn about your recoverable losses in NTNX: http://www.kleinstocklaw.com/pslra-1/nutanix-inc-loss-submission-form?id=13516&from=1
Astrazeneca Plc (NYSE:AZN)
Class Period: May 21, 2020 - November 20, 2020
Lead Plaintiff Deadline: March 29, 2021
The AZN lawsuit alleges that Astrazeneca Plc made materially false and/or misleading statements and/or failed to disclose that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.
Learn about your recoverable losses in AZN: http://www.kleinstocklaw.com/pslra-1/astrazeneca-plc-loss-submission-form?id=13516&from=1
XL Fleet Corp. (NYSE:XL)
Class Period: October 2, 2020 - March 2, 2021
Lead Plaintiff Deadline: May 7, 2021
The XL lawsuit alleges XL Fleet Corp. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) XL Fleet's salespeople were pressured to inflate their sales pipelines to boost the Company's reported sales and backlog; (2) at least 18 of the 33 customers that XL featured were inactive and had not placed an order since 2019; (3) XL's technology had been materially overstated and offered only 5% to 10% of fleet savings; (4) XL lacks the supply chain and engineers to roll out new products on the announced timelines; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in XL: http://www.kleinstocklaw.com/pslra-1/xl-fleet-corp-loss-submission-form?id=13516&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm